Collaboration will leverage HUYA's growing Chinese bioscience network
SAN DIEGO, April 21 /PRNewswire/ -- HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Abbott to identify and pursue proprietary preclinical and clinical drug candidates that originate in China.
Abbott will gain access to HUYA's growing Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country. HUYA has agreements in place with many of these organizations whereby HUYA has ongoing exclusive access to compounds and biologics in a variety of indications. HUYA is currently evaluating and following the progress of more than 600 lead, preclinical and clinical drug candidates.
"China has an extremely rich pool of drug candidates, which we are able to tap through our extensive network of partners," said Mireille Gingras, PhD, President and CEO of HUYA. "We've been effective in leveraging those relationships to the mutual benefit of our partners in the West and in China, and we're looking forward to a productive collaboration with Abbott."
HUYA's model is based on long-term relationships with its Chinese partners and this provides a continuous source of compounds, unlike a single compound strategy. Once a compound is licensed, the ongoing exchange of expertise and data lowers risk and facilitates rapid and efficient clinical development in both China and the West.
HUYA currently has two clinical stage drugs licensed from China in the therapeutic areas of Cardiovascular and Oncology for development in the West.
HUYA's innovative model benefits partners in the West and China
HUYA was one of the first companies to recognize China's potential to help meet the global need for pre-clinical and clinical stag
|SOURCE HUYA Bioscience International|
Copyright©2009 PR Newswire.
All rights reserved